Literature DB >> 24184737

Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.

Wout O Rohof1, Roelof J Bennink2, Hugo de Jonge3, Guy E Boeckxstaens4.   

Abstract

BACKGROUND & AIMS: Approximately 30% of patients with gastroesophageal reflux disease have symptoms resistant to treatment with proton pump inhibitors (PPIs). Several mechanisms such as esophageal hypersensitivity, increased mucosal permeability, and possibly the position of the gastric acid pocket might underlie a partial response to PPIs. To what extent these mechanisms interact and contribute to PPI-resistant symptoms, however, has not been investigated previously.
METHODS: In 18 gastroesophageal reflux disease patients (9 PPI responders and 9 PPI partial responders), esophageal sensitivity, mucosal permeability, and postprandial reflux parameters were determined during PPI use. Esophageal sensitivity for distension was measured by gradual balloon inflation at 5 and 15 cm above the lower esophageal sphincter. The mucosal permeability of 4 esophageal biopsy specimens per patient was determined in Ussing chambers by measuring the transepithelial electrical resistance and transmucosal flux of fluorescein. Postprandial reflux parameters were determined using concurrent high-resolution manometry/pH impedance after a standardized meal. In addition, the acid pocket was visualized using scintigraphy.
RESULTS: No difference in the rate of postprandial acid reflux, in the pH of the acid pocket (PPI responders 3.7 ± 0.7 vs PPI partial responders 4.2 ± 0.4; P = .54), or in the position of the acid pocket was observed in PPI partial responders compared with PPI responders. In addition, the permeability of the esophageal mucosa was similar in both groups, as shown by a similar transepithelial electrical resistance and flux of fluorescein. PPI partial responders had more reflux episodes with a higher mean proximal extent, compared with PPI responders, and were more sensitive to balloon distension, both in the upper and lower esophagus.
CONCLUSIONS: PPI-resistant symptoms most likely are explained by increased proximal reflux in a hypersensitive esophagus and less likely by increased mucosal permeability or the position of the acid pocket.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gastroesophageal Junction; Gastroesophageal Reflux Disease; Proton Pump Inhibitors

Mesh:

Substances:

Year:  2013        PMID: 24184737     DOI: 10.1016/j.cgh.2013.10.026

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  10 in total

Review 1.  Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure.

Authors:  Ofer Z Fass; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

2.  Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report.

Authors:  Yuyang Shao; Chen Xie; Huang Feng; Donglin Yan; Weichang Chen
Journal:  BMC Gastroenterol       Date:  2022-06-23       Impact factor: 2.847

3.  Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring.

Authors:  A Patel; G S Sayuk; C P Gyawali
Journal:  Neurogastroenterol Motil       Date:  2016-04-08       Impact factor: 3.598

4.  The Spectrum of Reflux Phenotypes.

Authors:  Lisa B Mahoney; Rachel Rosen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-12

5.  Reflux characteristics triggering post-reflux swallow-induced peristaltic wave (PSPW) in patients with GERD symptoms.

Authors:  Mentore Ribolsi; Marzio Frazzoni; Nicola De Bortoli; Salvatore Tolone; Elena Arsiè; Lucia Mariani; Giovanni De Carlo; Daria Maniero; Roberto Penagini; Michele Cicala; Edoardo Savarino
Journal:  Neurogastroenterol Motil       Date:  2021-05-29       Impact factor: 3.960

Review 6.  Symptomatic reflux disease: the present, the past and the future.

Authors:  Guy Boeckxstaens; Hashem B El-Serag; André J P M Smout; Peter J Kahrilas
Journal:  Gut       Date:  2014-03-07       Impact factor: 23.059

7.  Republished: symptomatic reflux disease: the present, the past and the future.

Authors:  Guy Boeckxstaens; Hashem B El-Serag; André J P M Smout; Peter J Kahrilas
Journal:  Postgrad Med J       Date:  2015-01       Impact factor: 2.401

8.  Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.

Authors:  Andreas Steingoetter; Matthias Sauter; Jelena Curcic; Dian Liu; Dieter Menne; Michael Fried; Mark Fox; Werner Schwizer
Journal:  BMC Gastroenterol       Date:  2015-09-02       Impact factor: 3.067

Review 9.  Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2018-03-21

10.  Acotiamide Has No Effects on Esophageal Motor Activity or Esophagogastric Junction Compliance.

Authors:  Hironobu Mikami; Norihisa Ishimura; Mayumi Okada; Daisuke Izumi; Eiko Okimoto; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.